You are here

Article Text

Article menu

Download PDFPDF

XML
Review
LncRNAs in genetic basis of glaucoma
  1. Yacouba Cissé,
  2. Lang Bai,
  3. Ting Meng
  1. Department of Ophthalmology, Nanfang Hospital, Southern Medical University, Guangzhou, China
  1. Correspondence to Dr Lang Bai; bailangsfy{at}126.com

Abstract

Glaucoma is an umbrella term used to designate a heterogeneous group of ocular disorders characterised by progressive excavation of the optic disc, optic atrophy and gradual loss of the visual field caused by the slow death of retinal ganglion cells and their axons. Glaucoma can potentially lead to blindness if left untreated. It usually starts from the periphery and progresses gradually toward the centre of the visual field. Vision loss caused by glaucoma is irreversible and causes a heavy burden on affected families and society, therefore the importance of early diagnosis and prevention should be emphasised. Genetic factors appear to play a role in glaucoma pathogenesis; it has been shown that individuals with a positive family history are at a greater risk because they are more likely predisposed be affected. Notable advances have been recorded in the past decade concerning the genetic and environmental factors likely to contribute or cause glaucoma with the discovery of multiple glaucoma-associated genes and genetic loci. Thorough investigations by a handful of studies on the function of long non-coding RNAs discovered that, although lacking protein-coding potential, lncRNAs can still participate in the regulation of gene expression at various levels, thus their possible implication in different disease aetiologies. In this review, we focus on the lncRNAs characteristics and its regulation, and summarise these results from separate, independent, glaucoma-related studies in addition to discussing possible pathways by which lncRNAs might contribute to glaucoma.

  • apotosis
  • optic nerve
  • genetics
  • aqueous humour
  • glaucoma
  • retina
  • intraocular pressure

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/bmjophth-2017-000131

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Introduction

    Glaucoma is an umbrella term used to designate a heterogeneous group of ocular disorders characterised by optic nerve damage that leads to vision loss and ultimately blindness if untreated and; usually starts from the periphery and progresses gradually towards the centre of the visual field.1

    The number of people with glaucoma (primary open angle glaucoma (POAG) and primary angle closure glaucoma (PACG) combined) worldwide was estimated to be around 60.5 million in 2010. This number will increase significantly in the future, and it has been estimated that by 2020, approximately 79.6 million people will be affected, including 3 million in the USA.2 3 According to recent studies, the number of people affected by glaucoma worldwide will reach 111.8 million by 2040, with Africa and Asia being most heavily affected.4 Chinese patients with PACG account for nearly half of PACG cases worldwide.3 According to the WHO, it is currently the leading cause of irreversible blindness worldwide, despite the existence of an indisputable variation in its subtypes and risks among races and countries.5

    Vision loss caused by glaucoma is irreversible and causes a heavy burden on affected families and society; therefore, the importance of early diagnosis through relevant examinations of suspicious cases to facilitate early detection and prevention; and avoid high intraocular pressure (IOP)-associated damage to the optic nerve should be emphasised.

    Genetic factors seem to play an undeniable role in glaucoma pathogenesis; it has been shown that individuals with a positive family history are at a greater risk because they have a predisposition towards the condition.6 7 Since the discovery of multiple glaucoma-associated genes and genetic loci in the past decade, notable advances have been recorded concerning the genetic and environmental factors likely to contribute to or cause glaucoma.8–10

    Recent recognition of the crucial functional importance of the non-coding region of the genome in normal development and physiology has focused increasing attention on its potential to contribute towards disease aetiology. IncRNAs are defined as non-protein-coding transcripts with a size ranging from 200 to 100 000 nt; although lacking protein-coding potential, lncRNAs can still participate as RNA in the regulation of gene expression at various levels and are reportedly implicated in different disease aetiologies.11

    Despite the fact that lncRNAs have been said to be implicated in normal neural development12 and progression of neurodegenerative diseases, including Alzheimer disease,13 and previously linked to multiple disease aetiologies, the proper connections and pathways they may use to influence the susceptibility to developing glaucoma, which is also characterised by nerve damage, have not yet been completely elucidated.

    In this article, we review underlining mechanisms and risk factors for developing glaucoma, focus on the characteristics and regulation of lncRNAs and aim to demonstrate their implication in glaucoma pathogenesis by summarising results from separate, independent, glaucoma-related studies.

    Genetic associations of lncRNA and glaucoma

    CDKN2B-AS1

    There are several genes in the 9p21 genomic region: CDKN2B-AS1, also known as ANRIL (antisense non-coding RNA in the INK4 locus); cyclin-dependent kinase inhibitor 2B (CDKN2B) and cyclin-dependent kinase inhibitor 2A (CDKN2A).14

    Recent genome-wide association studies (GWAS) have remarkably shown the association of single nucleotide polymorphisms (SNPs) in this region with various human diseases, including notably, coronary artery disease,15 diabetes,16 ischaemic stroke,17 cranial and aortic aneurysm,18 glioma,19 malignant melanoma20 as well as many cancers.19

    CDKN2B-AS1 is a long non-coding RNA in the antisense direction compared with CDKN2A and CDKN2B.21 Its exact biological function is largely unknown. The molecular mechanisms underlying the association between ANRIL and POAG are still not well understood.22 The occurrence of polymorphisms at these loci may alter the expression of the target genes responsible for regulating the cell cycle or act through epigenetic mechanisms, subsequently inducing a tendency towards retinal ganglion cell (RGC) apoptosis and glaucoma.23–25 Another study identified associations between 9p21 variants and glaucoma features, suggesting that the ANRIL region modifies the vulnerability of the optic nerve to cause glaucomatous change, further implying the role of ANRIL in modulating optic nerve degeneration.26

    Glaucoma-associated variants

    Numerous genetic variations have been associated with an increased risk of POAG in the past decade. The corresponding SNPs have been identified by different GWAS and are located in and around the CDKN2B-AS1.24 27 28 Actually, each glaucoma-associated SNP does in fact possess two alleles: one associated with a decreased POAG risk (protective variants) and the other one associated with an increased POAG risk (risk variants). Variants such as rs7049105 and rs2151280 were not only associated with a reduced POAG risk, but have also been linked with a smaller cup-to-disc ratio (CDR) observed at disease presentation. Although primarily associated with a reduced risk in case–control studies, an association was also established between rs573687 and the age at diagnosis of patients with POAG, with people carrying this allele developing the disease at least 5 years later than non-carriers.26

    The rs2157719 allele was described as not only having an association with an increased chance of peripheral visual field loss and smaller CDR, but is widely known to play a major role in the occurrence of both normal tension glaucoma (NTG) and exfoliation glaucoma. It has further been reported to be implicated in reduced POAG risk in Asian, African and Caucasian populations in diverse studies.23 29 rs32177992 was found to increase the risk of POAG, with carriers more prone to develop the disease and potentially harbouring a larger CDR at diagnosis. A larger optic disc has been shown to be more susceptible to IOP-related stress. Thus, this suggests an implication in the occurrence of glaucoma and the progressive increase in vertical cup-to-disc ratio (VCDR) found in patients with POAG.30

    Compared with patients who lack glaucoma risk alleles, patients carrying the risk alleles31 (rs7049105 and rs10120688) have a lower IOP and a larger VCDR32 and are predisposed to the development of POAG at lower IOP levels, with carriers recording nearly peak IOPs of 3 mm Hg less than non-carriers. In other words, these patients exhibit stronger associations with NTG and advanced glaucoma phenotypes.31 This finding demonstrates out that they might also be classed as severity markers for POAG. A free of adverse effects and lowering intraocular therapy is beneficial in patients at risk of disease progression.33

    The possible explanations for how these risk alleles may predispose or increase the risk of glaucoma are by conferring a risk non-dependent of IOP and by increasing the susceptibility to IOP, which means increasing the sensitivity of RGCs to IOP. Importantly, these risk alleles may manage to specifically affect both the regulation of IOP and the physiology of the RGC. Cell cycle regulation is known to be possibly affected by altered gene expression, leading the RGCs to a tendency towards apoptosis. Cells in carriers may then become more sensitive to IOP, such that pressures still contribute to optic nerve damage even when statistically normal.23

    Individuals exhibiting an elevated IOP without the presence of optic nerve damage may only carry genetic variants that can influence IOP regulation, while those with NTG may primarily carry genetic variants predisposed to RGC death, as the nerve degeneration in this case does not have the added stress of elevated IOP.33

    Regulation of CDKN2A and CDKN2B

    Two proteins are encoded by CDKN2A: p16INK4A and p14ARF, which regulate the cell cycle and act as tumour suppressors. CDKN2A products regulate the Rb (retinoblastoma protein) and p53 (phosphoprotein p53) pathways, which reportedly involved in RGC apoptosis and the induction of cell cycle arrest, apoptosis and senescence.34 CDKN2B encodes p15INK4B, a protein believed to play an important role in cell growth regulation through inducing G1 phase cell cycle arrest and is likely induced by transforming growth factor beta (TGF-β).35 TGF-β modulates developmental and repair processes in several tissues, as well as participates to a considerable degree in programmed cell death in the developing retina and optic nerve.36 37

    Patients with glucoma tend to have a higher aqueous humour concentration of TGF-β2 (the predominant isoform of TGF-β in ocular tissue) than normal individuals, suggesting a link between a high level of TGF-β2 and the pathogenesis of the disease.38 39 CDKN2B-AS1 apparently participates in the transcription regulation of CDKN2A/CDKN2B, and it has been noted that ANRIL depletion (deletion of the 3=end) in transgenic mice leads to excessive proliferation and diminished senescence in aortic smooth muscle cells, suggesting a key role in cell cycle regulation. Comparatively, the reduced cardiac expression of CDKN2A and CDKN2B in these mice was also pointed out and may be the mechanism through which CDKN2B-AS1 can alter cell cycle regulation.40 41

    To further decipher the nature of their interaction and involvement in the pathogenesis of glaucoma, researchers performed a PCR analysis of their expressions in a rat model of glaucoma. One week after ocular hypertension induction, an upregulation in the expression in CDKN2A and CDKN2B was observed in the retina, which corresponds to a time point of ongoing RGC death, as indicated by the presence of axonal cytoskeleton damage in the optic nerve of the animals studied.24 CDKN2A and CDKN2B seem to be involved in inducing apoptosis in response to stress in terminally differentiated neurons, which are of particular relevance to glaucoma, a disease characterised pathologically by the apoptosis of RGCs and loss of their axons.42

    According to previous research on animal studies, elevated IOP is implicated in the overexpression of CDKN2B, which is responsible for abnormal cell proliferation because it disrupts the normal cell cycle.43 CDKN2A, previously found to be down regulated in neurodegenerative disorders such as Alzheimer disease, can equally be regulated by CDKN2B-AS1, which suggest that regulation of CDKN2A by CDKN2B-AS1 could also contribute to degeneration of the optic nerve in glaucoma.25 44

    MALAT1

    Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), also known as non-coding nuclear-enriched abundant transcript 2 (NEAT2), is a long non-coding RNA highly expressed in the nucleus and located on chromosome 1145. It acts as a critical regulator of neurodegeneration and has been successfully identified in diverse physiological processes, and a variety of evidence indicates its implication in various pathological processes, including diabetes-induced retinal microvascular dysfunction.46

    MALAT1 participates in the regulation of the gene expression involved in nuclear and synapse function and synaptogenesis in neurons and has been demonstrated by previous studies to play a positive role in apoptosis, tumour cell proliferation, migration, invasion or the metastatic spread of tumour cells.47 48 Recent studies conducted to determine and define its role in retinal neurodegeneration not only discovered a significant upregulation of MALAT1 in the cerebellum, hippocampus and brain stem of human alcoholics49 and many solid tumours,50 but also revealed its possible involvement in diabetes-induced retinal microvascular dysfunction.46

    MALAT1 can promote cell proliferation by activating the PI3K/Akt pathway,51 52 and MALAT1 downregulation can lead to decreased visual function and retinal cell apoptosis.53 Further investigations on whether MALAT1 dysregulation can be equally observed in other neurological diseases such as glaucoma have been conducted by performing qRT–PCRs to compare MALAT1 levels in aqueous humour samples from glaucoma and cataracts patients without ocular neurodegenerative diseases. The results showed comparatively downregulated MALAT1 levels in the aqueous humour of patients with glaucoma.54

    Additional clinical and animal experiments discovered that MALAT1 knockdown may potentially affect the regenerative ability of Müller cells and contribute to the reduced expression of neurotrophic factor, thus decreasing the protection of the retina.54 The knockout of MALAT1 results in delayed vessel extension, reduced density at the vascular front and decreased proliferating cells. Microarray and quantitative PCR analyses further suggest that the promigratory and antiproliferative effects of silencing MALAT1 may be due to its downregulation of the S-phase cell cycle cyclins and upregulation of cell cycle inhibitory genes. These results implicate that during normal development, the high expression of lncRNA–MALAT1 in endothelial cells may help maintain proliferative state of these cells.55 Müller cells are the major glial component of the retina and participate in retinal homeostasis and intervene in the regulation of retinal blood flow.56 They are said to be reactivated (gliosis) in the retinas of patients with POAG, and their activation actually consists of releasing neurotrophic factors favouring the protection of the retina from a wide variety of pathological stimuli, including ischaemia, trauma and degeneration.57–59 Nonetheless, The disturbance of retinal metabolism or a primary Müller cell insufficiency, such as in certain forms of glaucoma, may participate in the production and release of cytotoxic factors, increase the susceptibility of neurons to stressful stimuli, and cause and/or aggravate neuronal cell death after undergoing a variety of changes in morphological, physiology and biochemistry features.60 61

    Nakazawa et al created an ischaemic model of optic nerve injury with optic nerve crush and found that PI3K/Akt pathway activation is actually responsible for the production of a neuroprotective effect against retinal and optic nerve injury.53

    Recent investigations on this protective effect and mechanism of MALAT1 in glaucomatous RGCs62 did provide strong evidence that MALAT1 could also be implicated in the inhibition process of RGC apoptosis through the activation of the PI3K/Akt signalling pathway. Since this inhibition process protects RGCs, inhibits the occurrence of apoptosis and promotes axonal regeneration in both glaucoma and optic neuropathy,63 64 it provides a new approach for the clinical treatment of these conditions.62

    LOXL1-AS1

    Exfoliation syndrome (XFS) or pseudoexfoliation syndrome (PXF) is an age-related blinding disorder characterised by the production and accumulation of abnormal extracellular material in both ocular and non-ocular tissues.65 XFS is the most common identifiable cause of open-angle glaucoma and affects 60–70 million people worldwide.66 Patients with XFS are allegedly at a greater risk of developing a specific form of glaucoma called exfoliation glaucoma (XFG), with roughly half of the eyes with XFS developing the disease within 15 years of diagnosis.67 XFG which accounts for approximately 25% of all glaucomas possesses comparatively advanced visual field defects, a higher IOP as well as a reduced response to medical treatment as main characteristics compared with POAG.68

    During pupillary movement, exfoliation material is scraped from the lens surface by the iris, causing a rupture of iris pigment epithelial cells and leading to pigment dispersion into the anterior chamber and its deposition on anterior chamber structures.

    The white deposit appearance of the material in the eye can be perceived on the anterior lens surface and/or pupillary border.69 Behavioural factors, such as caffeine intake, latitude of residence and vitamin deficiency, have been demonstrated to influence the risk of developing XFS and XFG.70–72

    The LOXL1 gene, a member of the lysyl oxidase family, participates in the formation and maintenance of elastic tissue and, by inducing cross-linking in collagen and elastin molecules, plays a significant role in maintaining the equilibrium of the extracellular matrix (ECM).73 It is expressed in ocular tissues, such as the cornea, ciliary muscle, lens epithelium, lamina cribrosa and trabecular meshwork, all of which are supposedly involved in the formation of the ECM. An alteration in its activation, processing and or substrate specificity can affect the function and synthesis of extracellular tissues.74 75

    LOXL1 polymorphisms have previously been suggested by a large number of studies to be associated with XFS in different populations, including Caucasians (Europe, Australia and North America), Asians (China and Japan) and South Africans.

    Unfortunately, these studies primarily produced inconclusive results because alleles that reportedly increase the risk of developing XFS and XFG among Caucasians (rs1048661 and rs3825942) were also shown to have a protective effect in Japanese populations.76–78 Further investigations into LOXL1 and its involvement in XFS pathogenesis discovered that the strongest evidence for an association with an increased XFS risk was located within the first intron of LOXL1, which contains variants that possibly alter the promoter for LOXL1-AS1.79

    LOXL1-AS1 (LOXL1 antisense RNA 1) is a long non-coding RNA that is encoded by the opposite strand of LOXL1. It is broadly expressed in tissues known to be affected in XFS, and its expression can be altered by XFS-relevant cell stressors, such as oxidative stress in lens epithelial cells and cyclic mechanical stress in Schlemm’s canal, suggesting a critical role in the cell stress response.79 80 The expression of many genes involved in various processes and XFG pathophysiology, such as collagen fibril formation (COL6A3, LOXL4), ECM degradation (TIMP3), cytoskeleton integrity (ACTA2), calcium ion binding (EFHD2), and response to oxidative stress (HMOX1), are actually modulated by the LOXL1-AS1.

    LOXL1-AS1 knockdown has been demonstrated to alter the expression of up to 109 genes, including those related to ECM constituents. The dysregulated expression of LOXL1-AS1 may contribute to XFS and XFG pathogenesis because genetic risk variants and environmental stressors altering the level of LOXL1-AS1 disrupt the equilibrium of the ECM by affecting the gene expression of other XFS-relevant genes, potentially contributing to the pathogenesis of these complex inherited diseases.81

    Additionally, it has been proven that the altered expression of LOXL1-AS1 levels has functional relevance in other organs and tissues affected in XFS including stem cells. This implies the possible implication of LOXL1-AS1 in increasing the risk of cerebrovascular diseases in patients with XFS. Similarly, increased oxidative stress is observed in neurodegenerative disorders, which are also associated with XFS, suggesting that LOXL1-AS1 dysregulation and abnormal response to oxidative stress play a role in these disease states.82

    ASMM10P055228 and ASMM10P040128

    Optineurin, also called optic neuropathy-inducing protein, is a protein that is encoded by the OPTN gene and the second identified glaucoma causative gene through investigations of large NTG pedigrees.83 The OPTN gene is located on chromosome 10p15-14, ubiquitously expressed in both non-ocular and ocular tissues84 that include the trabecular meshwork, non-pigmented ciliary epithelium, retina, brain, heart, skeletal muscle, placenta and kidney; and mutations in this gene have been linked to POAG and NTG.85

    OPTN mutations in transgenic mice models, including E50, have been identified as a key element in RGC apoptosis in previous studies; however, specific mechanisms remain largely unknown.86 Recent studies have aimed to investigate the expression of differentially expressed lncRNAs in OPTN (E50K) transgenic and wild-type mice. For this purpose, six retinas from 8-month-old transgenic and wild-type mice were collected, divided into different groups and analysed independently for levels of lncRNA expression, which were later compared between mutant and wild groups by performing a two-tailed t-test.

    The results revealed various differentially expressed lncRNAs between the OPTN (E50K) transgenic and wild-type mice; in addition, the pathway analysis contributed to the annotation of ASMM10P055228 and ASMM10P040128, two lncRNAs suspected to be responsible for the negative regulation of oxidative stress-induced cell death and regulation of the execution phase of apoptosis, which may be the underlying mechanism for POAG.

    Although observations about the discovery of differentially expressed lncRNAs in the retinas between OPTN (E50K) transgenic and wild-type mice remain preliminary;and require further investigations to help clarify pathogenetic pathways, this finding is still attracting increasing interest as it creates a paradigm regarding the function of lncRNAs for detecting POAG pathogenesis.87

    Conclusion

    Glaucoma is a complex disease because genetic and environmental factors both play important roles in its pathogenesis, therefore and despite the tremendous progress achieved in the last decade, the genetic basis of glaucoma is still not completely understood. Although lncRNAs have previously been linked with diverse diseases, however the proper connections and pathways they may use to influence the susceptibility to developing glaucoma have not yet been completely elucidated.

    By summarising results from separate independent glaucoma-related studies, we reviewed lncRNAs characteristics and regulation, and tried to discuss potential pathways by which CDKN2B-AS1, MALAT1, LOXL1-AS1, ASMM10P055228 and ASMM10P040128 may contribute to glaucoma.

    However, further researches and investigations are needed to discover vast number of glaucoma-associated lncRNAs, their characteristics and expression patterns, and decipher pathways of their involvement and role in the pathogenesis of this blinding disease. Since most glaucomas are symptomless at early stages, we stress that this article creates a paradigm for future studies of lncRNAs in the prevention, early determination and monitoring of the evolution of glaucoma and may prove to be useful to define high-risk or low-risk alleles for early determination of whether a patient with a suspected glaucoma allele should receive prioritised treatment to help slow the progression of the disease, reduce further damage to the optic nerve and subsequently avoid blindness, and retain quality of life.

    Acknowledgments

    The authors are thankful to all members of Bai Lang’s research group for their participation and critical assessments of this manuscript .

    References

    1. 1.↵
      2. Mantravadi AV ,
      3. Vadhar N
      . Glaucoma. Prim Care 2015;42:437–49.doi:10.1016/j.pop.2015.05.008
      OpenUrl
    2. 2.↵
      2. Friedman DS ,
      3. Wolfs RC ,
      4. O’Colmain BJ , et al
      . Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122:532–8.doi:10.1001/archopht.122.4.532
      OpenUrlCrossRefPubMedWeb of Science
    3. 3.↵
      2. Quigley HA ,
      3. Broman AT
      . The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262–7.doi:10.1136/bjo.2005.081224
      OpenUrlAbstract/FREE Full Text
    4. 4.↵
      2. Tham YC ,
      3. Li X ,
      4. Wong TY , et al
      . Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014;121:2081–90.doi:10.1016/j.ophtha.2014.05.013
      OpenUrlCrossRefPubMedWeb of Science
    5. 5.↵
    6. 6.↵
      2. Klein BE ,
      3. Klein R ,
      4. Lee KE
      . Heritability of risk factors for primary open-angle glaucoma: the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci 2004;45:59–62.doi:10.1167/iovs.03-0516
      OpenUrlAbstract/FREE Full Text
    7. 7.↵
      2. Kong X ,
      3. Chen Y ,
      4. Chen X , et al
      . Influence of family history as a risk factor on primary angle closure and primary open angle glaucoma in a Chinese population. Ophthalmic Epidemiol 2011;18:226–32.doi:10.3109/09286586.2011.595040
      OpenUrlCrossRefPubMed
    8. 8.↵
      2. Stone EM ,
      3. Fingert JH ,
      4. Alward WL , et al
      . Identification of a gene that causes primary open angle glaucoma. Science 1997;275:668–70.doi:10.1126/science.275.5300.668
      OpenUrlAbstract/FREE Full Text
    9. 9.↵
      2. Rezaie T ,
      3. Child A ,
      4. Hitchings R , et al
      . Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science 2002;295:1077–1079.doi:10.1126/science.1066901
      OpenUrlAbstract/FREE Full Text
    10. 10.↵
      2. Chen Y ,
      3. Chen X ,
      4. Wang L , et al
      . Extended association study of PLEKHA7 and COL11A1 with primary angle closure glaucoma in a Han Chinese population. Invest Ophthalmol Vis Sci 2014;55:3797–802.doi:10.1167/iovs.14-14370
      OpenUrlAbstract/FREE Full Text
    11. 11.↵
      2. Esteller M
      . Non-coding RNAs in human disease. Nat Rev Genet 2011;12:861–74.doi:10.1038/nrg3074
      OpenUrlCrossRefPubMed
    12. 12.↵
      2. Ramos AD ,
      3. Andersen RE ,
      4. Liu SJ , et al
      . The long noncoding RNA Pnky regulates neuronal differentiation of embryonic and postnatal neural stem cells. Cell Stem Cell 2015;16:439–47.doi:10.1016/j.stem.2015.02.007
      OpenUrlCrossRefPubMed
    13. 13.↵
      2. Faghihi MA ,
      3. Modarresi F ,
      4. Khalil AM , et al
      . Expression of a noncoding RNA is elevated in Alzheimer’s disease and drives rapid feed-forward regulation of beta-secretase. Nat Med 2008;14:723–30.doi:10.1038/nm1784
      OpenUrlCrossRefPubMedWeb of Science
    14. 14.↵
      2. Greene LA ,
      3. Liu DX ,
      4. Troy CM , et al
      . Cell cycle molecules define a pathway required for neuron death in development and disease. Biochim Biophys Acta 2007;1772:392–401.doi:10.1016/j.bbadis.2006.12.003
      OpenUrlCrossRefPubMedWeb of Science
    15. 15.↵
      2. Helgadottir A ,
      3. Thorleifsson G ,
      4. Manolescu A , et al
      . A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007;316:1491–3.doi:10.1126/science.1142842
      OpenUrlAbstract/FREE Full Text
    16. 16.↵
      2. Scott LJ ,
      3. Mohlke KL ,
      4. Bonnycastle LL , et al
      . A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007;316:1341–5.doi:10.1126/science.1142382
      OpenUrlAbstract/FREE Full Text
    17. 17.↵
      2. Matarin M ,
      3. Brown WM ,
      4. Singleton A , et al
      . Whole genome analyses suggest ischemic stroke and heart disease share an association with polymorphisms on chromosome 9p21. Stroke 2008;39:1586–9.doi:10.1161/STROKEAHA.107.502963
      OpenUrlAbstract/FREE Full Text
    18. 18.↵
      2. Helgadottir A ,
      3. Thorleifsson G ,
      4. Magnusson KP , et al
      . The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 2008;40:217–24.doi:10.1038/ng.72
      OpenUrlCrossRefPubMedWeb of Science
    19. 19.↵
      2. Shete S ,
      3. Hosking FJ ,
      4. Robertson LB , et al
      . Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 2009;41:899–904.doi:10.1038/ng.407
      OpenUrlCrossRefPubMedWeb of Science
    20. 20.↵
      2. Bishop DT ,
      3. Demenais F ,
      4. Iles MM , et al
      . Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009;41:920–5.doi:10.1038/ng.411
      OpenUrlCrossRefPubMedWeb of Science
    21. 21.↵
      2. Pasmant E ,
      3. Sabbagh A ,
      4. Vidaud M , et al
      . ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. Faseb J 2011;25:444–8.doi:10.1096/fj.10-172452
      OpenUrlAbstract/FREE Full Text
    22. 22.↵
      2. Ng SK ,
      3. Casson RJ ,
      4. Burdon KP , et al
      . Chromosome 9p21 primary open-angle glaucoma susceptibility locus: a review. Clin Exp Ophthalmol 2014;42:25–32.doi:10.1111/ceo.12234
      OpenUrl
    23. 23.↵
      2. Wiggs JL ,
      3. Yaspan BL ,
      4. Hauser MA , et al
      . Common variants at 9p21 and 8q22 are associated with increased susceptibility to optic nerve degeneration in glaucoma. PLoS Genet 2012;8:e1002654.doi:10.1371/journal.pgen.1002654
    24. 24.↵
      2. Burdon KP ,
      3. Macgregor S ,
      4. Hewitt AW , et al
      . Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1. Nat Genet 2011;43:574–8.doi:10.1038/ng.824
      OpenUrlCrossRefPubMed
    25. 25.↵
      2. Congrains A ,
      3. Kamide K ,
      4. Ohishi M , et al
      . ANRIL: molecular mechanisms and implications in human health. Int J Mol Sci 2013;14:1278–92.doi:10.3390/ijms14011278
      OpenUrlCrossRefPubMed
    26. 26.↵
      2. Pasquale LR ,
      3. Loomis SJ ,
      4. Kang JH , et al
      . CDKN2B-AS1 genotype-glaucoma feature correlations in primary open-angle glaucoma patients from the United States. Am J Ophthalmol 2013;155:342–53.doi:10.1016/j.ajo.2012.07.023
      OpenUrlCrossRefPubMed
    27. 27.↵
      2. Nakano M ,
      3. Ikeda Y ,
      4. Tokuda Y , et al
      . Common variants in CDKN2B-AS1 associated with optic-nerve vulnerability of glaucoma identified by genome-wide association studies in Japanese. PLoS One 2012;7:e33389.doi:10.1371/journal.pone.0033389
      OpenUrlCrossRefPubMed
    28. 28.↵
      2. Osman W ,
      3. Low SK ,
      4. Takahashi A , et al
      . A genome-wide association study in the Japanese population confirms 9p21 and 14q23 as susceptibility loci for primary open angle glaucoma. Hum Mol Genet 2012;21:2836–42.doi:10.1093/hmg/dds103
      OpenUrlCrossRefPubMedWeb of Science
    29. 29.↵
      2. Li Z ,
      3. Allingham RR ,
      4. Nakano M , et al
      . A common variant near TGFBR3 is associated with primary open angle glaucoma. Hum Mol Genet 2015;24:3880–92.doi:10.1093/hmg/ddv128
      OpenUrlCrossRefPubMed
    30. 30.↵
      2. Bellezza AJ ,
      3. Hart RT ,
      4. Burgoyne CF
      . The optic nerve head as a biomechanical structure: initial finite element modeling. Invest Ophthalmol Vis Sci 2000;41:2991–3000.
      OpenUrlAbstract/FREE Full Text
    31. 31.↵
      2. Burdon KP ,
      3. Crawford A ,
      4. Casson RJ , et al
      . Glaucoma risk alleles at CDKN2B-AS1 are associated with lower intraocular pressure, normal-tension glaucoma, and advanced glaucoma. Ophthalmology 2012;119:1539–45.doi:10.1016/j.ophtha.2012.02.004
      OpenUrlCrossRefPubMedWeb of Science
    32. 32.↵
      2. Ramdas WD ,
      3. van Koolwijk LM ,
      4. Ikram MK , et al
      . A genome-wide association study of optic disc parameters. PLoS Genet 2010;6:e1000978.doi:10.1371/journal.pgen.1000978
      OpenUrlCrossRefPubMed
    33. 33.↵
      Group CN-TGS. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998;126:487–97.
      OpenUrlCrossRefPubMedWeb of Science
    34. 34.↵
      2. Gil J ,
      3. Peters G
      . Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 2006;7:667–77.doi:10.1038/nrm1987
      OpenUrlCrossRefPubMedWeb of Science
    35. 35.↵
      2. Hannon GJ ,
      3. Beach D
      . p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994;371:257–61.doi:10.1038/371257a0
      OpenUrlCrossRefPubMedWeb of Science
    36. 36.↵
      2. Pena JD ,
      3. Taylor AW ,
      4. Ricard CS , et al
      . Transforming growth factor beta isoforms in human optic nerve heads. Br J Ophthalmol 1999;83:209–18.doi:10.1136/bjo.83.2.209
      OpenUrlCrossRefPubMedWeb of Science
    37. 37.↵
      2. Duenker N
      . Transforming growth factor-beta (TGF-beta) and programmed cell death in the vertebrate retina. Int Rev Cytol 2005;245:17–43.doi:10.1016/S0074-7696(05)45002-0
      OpenUrlCrossRefPubMedWeb of Science
    38. 38.↵
      2. Ozcan AA ,
      3. Ozdemir N ,
      4. Canataroglu A
      . The aqueous levels of TGF-beta2 in patients with glaucoma. Int Ophthalmol 2004;25:19–22.doi:10.1023/B:INTE.0000018524.48581.79
      OpenUrlCrossRefPubMed
    39. 39.↵
      2. Trivedi RH ,
      3. Nutaitis M ,
      4. Vroman D , et al
      . Influence of race and age on aqueous humor levels of transforming growth factor-beta 2 in glaucomatous and nonglaucomatous eyes. J Ocul Pharmacol Ther 2011;27:477–80.doi:10.1089/jop.2010.0100
      OpenUrlCrossRefPubMed
    40. 40.↵
      2. Visel A ,
      3. Zhu Y ,
      4. May D , et al
      . Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature 2010;464:409–12.doi:10.1038/nature08801
      OpenUrlCrossRefPubMedWeb of Science
    41. 41.↵
      2. Fuchshofer R
      . The pathogenic role of transforming growth factor-β2 in glaucomatous damage to the optic nerve head. Exp Eye Res 2011;93:165–9.doi:10.1016/j.exer.2010.07.014
      OpenUrlCrossRefPubMedWeb of Science
    42. 42.↵
      2. Currais A ,
      3. Hortobágyi T ,
      4. Soriano S
      . The neuronal cell cycle as a mechanism of pathogenesis in Alzheimer’s disease. Aging 2009;1:363–71.doi:10.18632/aging.100045
      OpenUrlPubMedWeb of Science
    43. 43.↵
      2. Iglesias AI ,
      3. Springelkamp H ,
      4. van der Linde H , et al
      . Exome sequencing and functional analyses suggest that SIX6 is a gene involved in an altered proliferation-differentiation balance early in life and optic nerve degeneration at old age. Hum Mol Genet 2014;23:1320–32.doi:10.1093/hmg/ddt522
      OpenUrlCrossRefPubMedWeb of Science
    44. 44.↵
      2. Pogue AI ,
      3. Cui JG ,
      4. Li YY , et al
      . Micro RNA-125b (miRNA-125b) function in astrogliosis and glial cell proliferation. Neurosci Lett 2010;476:18–22.doi:10.1016/j.neulet.2010.03.054
      OpenUrlCrossRefPubMedWeb of Science
    45. 45.↵
      2. Hutchinson JN ,
      3. Ensminger AW ,
      4. Clemson CM , et al
      . A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. BMC Genomics 2007;8:39.doi:10.1186/1471-2164-8-39
      OpenUrlCrossRefPubMed
    46. 46.↵
      2. Liu JY ,
      3. Yao J ,
      4. Li XM , et al
      . Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus. Cell Death Dis 2014;5:e1506.doi:10.1038/cddis.2014.466
    47. 47.↵
      2. Qiu MT ,
      3. Hu JW ,
      4. Yin R , et al
      . Long noncoding RNA: an emerging paradigm of cancer research. Tumour Biol 2013;34:613–20.doi:10.1007/s13277-013-0658-6
      OpenUrlCrossRefPubMed
    48. 48.↵
      2. Bernard D ,
      3. Prasanth KV ,
      4. Tripathi V , et al
      . A long nuclear-retained non-coding RNA regulates synaptogenesis by modulating gene expression. Embo J 2010;29:3082–93.doi:10.1038/emboj.2010.199
      OpenUrlAbstract/FREE Full Text
    49. 49.↵
      2. Kryger R ,
      3. Fan L ,
      4. Wilce PA , et al
      . MALAT-1, a non protein-coding RNA is upregulated in the cerebellum, hippocampus and brain stem of human alcoholics. Alcohol 2012;46:629–34.doi:10.1016/j.alcohol.2012.04.002
      OpenUrlCrossRefPubMed
    50. 50.↵
      2. Gutschner T ,
      3. Hämmerle M ,
      4. Diederichs S
      . MALAT1 – a paradigm for long noncoding RNA function in cancer. J Mol Med 2013;91:791–801.doi:10.1007/s00109-013-1028-y
      OpenUrlCrossRefPubMed
    51. 51.↵
      2. Zhao J ,
      3. Li L ,
      4. Peng L
      . MAPK1 up-regulates the expression of MALAT1 to promote the proliferation of cardiomyocytes through PI3K/AKT signaling pathway. Int J Clin Exp Pathol 2015;8:15947–53.
      OpenUrl
    52. 52.↵
      2. Dong Y ,
      3. Liang G ,
      4. Yuan B , et al
      . MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol 2015;36:1477–86.doi:10.1007/s13277-014-2631-4
      OpenUrlCrossRefPubMed
    53. 53.↵
      2. Nakazawa T ,
      3. Shimura M ,
      4. Tomita H , et al
      . Intrinsic activation of PI3K/Akt signaling pathway and its neuroprotective effect against retinal injury. Curr Eye Res 2003;26:55–63.doi:10.1076/ceyr.26.1.55.14254
      OpenUrlCrossRefPubMedWeb of Science
    54. 54.↵
      2. Yao J ,
      3. Wang XQ ,
      4. Li YJ , et al
      . Long non-coding RNA MALAT1 regulates retinal neurodegeneration through CREB signaling. EMBO Mol Med 2016;8:346–62.doi:10.15252/emmm.201505725
      OpenUrlAbstract/FREE Full Text
    55. 55.↵
      2. Michalik KM ,
      3. You X ,
      4. Manavski Y , et al
      . Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res 2014;114:1389–97.doi:10.1161/CIRCRESAHA.114.303265
      OpenUrlAbstract/FREE Full Text
    56. 56.↵
      2. Bringmann A ,
      3. Pannicke T ,
      4. Grosche J , et al
      . Müller cells in the healthy and diseased retina. Prog Retin Eye Res 2006;25:397–424.doi:10.1016/j.preteyeres.2006.05.003
      OpenUrlCrossRefPubMedWeb of Science
    57. 57.↵
      2. Barres BA
      . The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 2008;60:430–40.doi:10.1016/j.neuron.2008.10.013
      OpenUrlCrossRefPubMedWeb of Science
    58. 58.↵
      2. Mamczur P ,
      3. Borsuk B ,
      4. Paszko J , et al
      . Astrocyte-neuron crosstalk regulates the expression and subcellular localization of carbohydrate metabolism enzymes. Glia 2015;63:328–40.doi:10.1002/glia.22753
      OpenUrlCrossRefPubMed
    59. 59.↵
      2. Ruzafa N ,
      3. Vecino E
      . Effect of Müller cells on the survival and neuritogenesis in retinal ganglion cells. Arch Soc Esp Oftalmol 2015;90:522–6.doi:10.1016/j.oftal.2015.03.009
      OpenUrl
    60. 60.↵
      2. Gao F ,
      3. Ji M ,
      4. Wu JH , et al
      . [Roles of retinal Müller cells in health and glaucoma]. Sheng Li Xue Bao 2013;65:654–-63.
      OpenUrl
    61. 61.↵
      2. Seitz R ,
      3. Ohlmann A ,
      4. Tamm ER
      . The role of Müller glia and microglia in glaucoma. Cell Tissue Res 2013;353:339–45.doi:10.1007/s00441-013-1666-y
      OpenUrlCrossRefPubMed
    62. 62.↵
      2. Li HB ,
      3. You QS ,
      4. Xu LX , et al
      . Long Non-Coding RNA-MALAT1 Mediates Retinal Ganglion Cell Apoptosis Through the PI3K/Akt Signaling Pathway in Rats with Glaucoma. Cell Physiol Biochem 2017;43:2117–32.doi:10.1159/000484231
      OpenUrl
    63. 63.↵
      2. Luo JM ,
      3. Cen LP ,
      4. Zhang XM , et al
      . PI3K/akt, JAK/STAT and MEK/ERK pathway inhibition protects retinal ganglion cells via different mechanisms after optic nerve injury. Eur J Neurosci 2007;26:828–42.doi:10.1111/j.1460-9568.2007.05718.x
      OpenUrlCrossRefPubMed
    64. 64.↵
      2. Li SY ,
      3. Yau SY ,
      4. Chen BY , et al
      . Enhanced survival of melanopsin-expressing retinal ganglion cells after injury is associated with the PI3 K/Akt pathway. Cell Mol Neurobiol 2008;28:1095–107.doi:10.1007/s10571-008-9286-x
      OpenUrlCrossRefPubMed
    65. 65.↵
      2. Miglior S ,
      3. Bertuzzi F
      . Exfoliative glaucoma: new evidence in the pathogenesis and treatment. Prog Brain Res 2015;221:233–41.doi:10.1016/bs.pbr.2015.06.007
      OpenUrl
    66. 66.↵
      2. Ritch R
      . Exfoliation syndrome-the most common identifiable cause of open-angle glaucoma. J Glaucoma 1994;3:176–7.doi:10.1097/00061198-199400320-00018
      OpenUrlPubMed
    67. 67.↵
      2. Jeng SM ,
      3. Karger RA ,
      4. Hodge DO , et al
      . The risk of glaucoma in pseudoexfoliation syndrome. J Glaucoma 2007;16:117–21.doi:10.1097/01.ijg.0000243470.13343.8b
      OpenUrlCrossRefPubMedWeb of Science
    68. 68.↵
      2. Vesti E ,
      3. Kivelä T
      . Exfoliation syndrome and exfoliation glaucoma. Prog Retin Eye Res 2000;19:345–68.doi:10.1016/S1350-9462(99)00019-1
      OpenUrlCrossRefPubMedWeb of Science
    69. 69.↵
      2. Ritch R
      . Ocular and systemic manifestations of exfoliation syndrome. J Glaucoma 2014;23:S1–S8.doi:10.1097/IJG.0000000000000119
      OpenUrl
    70. 70.↵
      2. Stein JD ,
      3. Pasquale LR ,
      4. Talwar N , et al
      . Geographic and climatic factors associated with exfoliation syndrome. Arch Ophthalmol 2011;129:1053–60.doi:10.1001/archophthalmol.2011.191
      OpenUrlCrossRefPubMedWeb of Science
    71. 71.↵
      2. Pasquale LR ,
      3. Wiggs JL ,
      4. Willett WC , et al
      . The Relationship between caffeine and coffee consumption and exfoliation glaucoma or glaucoma suspect: a prospective study in two cohorts. Invest Ophthalmol Vis Sci 2012;53:6427–33.doi:10.1167/iovs.12-10085
      OpenUrlAbstract/FREE Full Text
    72. 72.↵
      2. Kang JH ,
      3. Loomis SJ ,
      4. Wiggs JL , et al
      . A prospective study of folate, vitamin B₆, and vitamin B₁₂ intake in relation to exfoliation glaucoma or suspected exfoliation glaucoma. JAMA Ophthalmol 2014;132:549–59.doi:10.1001/jamaophthalmol.2014.100
      OpenUrl
    73. 73.↵
      2. Csiszar K
      . Lysyl oxidases: a novel multifunctional amine oxidase family. Prog Nucleic Acid Res Mol Biol 2001;70:1–32.
      OpenUrlCrossRefPubMedWeb of Science
    74. 74.↵
      2. Pena JD ,
      3. Netland PA ,
      4. Vidal I , et al
      . Elastosis of the lamina cribrosa in glaucomatous optic neuropathy. Exp Eye Res 1998;67:517–24.doi:10.1006/exer.1998.0539
      OpenUrlCrossRefPubMedWeb of Science
    75. 75.↵
      2. Kirwan RP ,
      3. Fenerty CH ,
      4. Crean J , et al
      . Influence of cyclical mechanical strain on extracellular matrix gene expression in human lamina cribrosa cells in vitro. Mol Vis 2005;11:798–810.
      OpenUrlPubMedWeb of Science
    76. 76.↵
      2. Álvarez L ,
      3. García M ,
      4. González-Iglesias H , et al
      . LOXL1 gene variants and their association with pseudoexfoliation glaucoma (XFG) in Spanish patients. BMC Med Genet 2015;16:72.doi:10.1186/s12881-015-0221-y
      OpenUrl
    77. 77.↵
      2. Jonasson F
      . From epidemiology to lysyl oxidase like one (LOXL1) polymorphisms discovery: phenotyping and genotyping exfoliation syndrome and exfoliation glaucoma in Iceland. Acta Ophthalmol 2009;87:478–87.doi:10.1111/j.1755-3768.2009.01635.x
      OpenUrlPubMed
    78. 78.↵
      2. Ramprasad VL ,
      3. George R ,
      4. Soumittra N , et al
      . Association of non-synonymous single nucleotide polymorphisms in the LOXL1 gene with pseudoexfoliation syndrome in India. Mol Vis 2008;14:318-–22.
      OpenUrlPubMedWeb of Science
    79. 79.↵
      2. Hauser MA ,
      3. Aboobakar IF ,
      4. Liu Y , et al
      . Genetic variants and cellular stressors associated with exfoliation syndrome modulate promoter activity of a lncRNA within the LOXL1 locus. Hum Mol Genet 2015;24:6552–63.doi:10.1093/hmg/ddv347
      OpenUrlCrossRefPubMed
    80. 80.↵
      2. Aboobakar IF ,
      3. Johnson WM ,
      4. Stamer WD , et al
      . Major review: exfoliation syndrome; advances in disease genetics, molecular biology, and epidemiology. Exp Eye Res 2017;154:88–103.doi:10.1016/j.exer.2016.11.011
      OpenUrl
    81. 81.↵
      2. Aboobakar IF ,
      3. Qin X ,
      4. Stamer WD , et al
      . A lncRNA in the LOXL1 locus modulates expression of genes relevant to exfoliation glaucoma pathobiology. Invest Ophthalmol Vis Sci 2016;57:790–90.
      OpenUrl
    82. 82.↵
      2. Ramalingam M ,
      3. Kim SJ
      . Reactive oxygen/nitrogen species and their functional correlations in neurodegenerative diseases. J Neural Transm 2012;119:891–910.doi:10.1007/s00702-011-0758-7
      OpenUrlCrossRefPubMedWeb of Science
    83. 83.↵
      2. Rezaie T ,
      3. Child A ,
      4. Hitchings R , et al
      . Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science 2002;295:1077–9.doi:10.1126/science.1066901
      OpenUrlAbstract/FREE Full Text
    84. 84.↵
      2. Sarfarazi M ,
      3. Rezaie T
      . Optineurin in primary open angle glaucoma. Ophthalmol Clin North Am 2003;16:529–41.doi:10.1016/S0896-1549(03)00061-0
      OpenUrlCrossRefPubMed
    85. 85.↵
      2. Fuse N ,
      3. Takahashi K ,
      4. Akiyama H , et al
      . Molecular genetic analysis of optineurin gene for primary open-angle and normal tension glaucoma in the Japanese population. J Glaucoma 2004;13:299–303.doi:10.1097/00061198-200408000-00007
      OpenUrlCrossRefPubMedWeb of Science
    86. 86.↵
      2. Chi ZL ,
      3. Akahori M ,
      4. Obazawa M , et al
      . Overexpression of optineurin E50K disrupts Rab8 interaction and leads to a progressive retinal degeneration in mice. Hum Mol Genet 2010;19:2606–15.doi:10.1093/hmg/ddq146
      OpenUrlCrossRefPubMedWeb of Science
    87. 87.↵
      2. Li Y ,
      3. Jin L ,
      4. Dong A , et al
      . Microarray expression profile analysis of long non-coding RNAs in optineurin E50K mutant transgenic mice. Mol Med Rep 2017;16:1255–61.doi:10.3892/mmr.2017.6722
      OpenUrl

    Footnotes

    • Contributors CY: conception, design, literature search and writing of the manuscript. BL: supervision. BL and MT: critical reading. All authors: approval of the final proofs of the article.

    • Funding This research is supported by the National Natural Science Foundation of China (Grant No. 81170887), the Natural Science Foundation of Guangdong Province (Grant No. 2017A030313602) and the Horizontal Topic Matching Funds of Nanfang Hospital, Southern Medical University (Grant No. G201202).

    • Competing interests None declared.

    • Patient consent Detail has been removed from this case description/these case descriptions to ensure anonymity. The editors and reviewers have seen the detailed information available and are satisfied that the information backs up the case the authors are making.

    • Provenance and peer review Not commissioned; internally peer reviewed.